

## RESOMER® MD biodegradable polymers receive ISO 13485 certification

February 6, 2017

Essen, Germany. Evonik's RESOMER® brand of biodegradable polymers for medical device (MD) applications is now certified to the ISO 13485 standard, which specifically governs MD products. The bioabsorbable polymers and copolymers are used to manufacture commercial bioresorbable implants.

**Contact person specialized press**

**Dr. Jürgen Krauter**

Vice President Communications

Phone +49 6181 59-6847

Fax +49 6181 59-76847

juergen.krauter@evonik.com

A comprehensive audit conducted by DQS Medizinprodukte GmbH in late November 2016 confirmed that RESOMER® products comply with all requirements defined in ISO 13485. In particular, DQS examined Evonik's risk management system and its quality assurance and documentation processes. The next recertification will take place in one year.

**Contact person specialized press**

**Hannah Rausche**

Head of Communications

Health Care

Phone +49 6151 18-3567

Fax +49 6181 59-76847

hannah.rausche@evonik.com

Quality and safety play a central role in the manufacture of medical devices. With this in mind, Evonik supports customers operating in this market by providing high-quality products – making a key contribution to their success.

### Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

### About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around €4.9 billion in 2015.

### Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

**Evonik Nutrition & Care GmbH**

Rellinghauser Straße 1-11

45128 Essen

Phone +49 201 177-01

Fax +49 201 177-3475

Germany

www.evonik.com

**Supervisory Board**

Dr. Ralph Sven Kaufmann, Chairman

**Management Board**

Dr. Reiner Beste, Chairman

Dr. Hans Josef Ritzert

Michael Gattermann

Markus Schäfer

Registered office Essen

Registered court

Essen local court

Commercial registry B 25784

HR no. FN 431387 v